X4 Pharmaceuticals Secures $27 Million in Series B FinancingProceeds Will Support Advancement of a Pivotal Study in a Rare Disease and Multiple Proof of Concept Studies in Immuno-Oncology CAMBRIDGE, Mass., November 16, 2017-- X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced the successful completion of a $27 million Series B financing. Proceeds from the financing will be used to advance X4’s two lead drug candidates in clinical efficacy studies in immuno-oncology and a pivotal study in WHIM syndrome, a rare primary immunodeficiency disease.